ALX-001 / Allyx Therap 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  ALX-001 / Allyx Therap
    Trial completion date, Trial primary completion date:  A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease (clinicaltrials.gov) -  Jul 30, 2024   
    P1,  N=50, Recruiting, 
    The longitudinal application of fMRI has enabled us to define the preclinical time trajectory of AD-related changes in functional connectivity, and to demonstrate a translatable metric for monitoring disease emergence, progression, and response to synapse-rescuing treatment. Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
  • ||||||||||  ALX-001 / Allyx Therap
    Trial completion date:  Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers (clinicaltrials.gov) -  Jul 29, 2024   
    P1,  N=12, Active, not recruiting, 
    Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025 Trial completion date: Jun 2024 --> Nov 2024
  • ||||||||||  ALX-001 / Allyx Therap
    Trial completion date:  Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers (clinicaltrials.gov) -  Oct 19, 2023   
    P1,  N=12, Active, not recruiting, 
    Phase classification: P1b --> P1 | Trial primary completion date: Oct 2024 --> Jul 2024 Trial completion date: Aug 2023 --> Jun 2024
  • ||||||||||  ALX-001 / Allyx Therap
    Trial completion date:  Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers (clinicaltrials.gov) -  Jul 20, 2023   
    P1,  N=12, Active, not recruiting, 
    Trial completion date: Jul 2024 --> Nov 2024 | Trial primary completion date: Jul 2024 --> Oct 2024 Trial completion date: May 2023 --> Aug 2023
  • ||||||||||  ALX-001 / Allyx Therap
    Trial completion, Trial completion date, Trial primary completion date:  Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923 (clinicaltrials.gov) -  Oct 5, 2022   
    P1,  N=36, Completed, 
    Trial completion date: May 2023 --> Aug 2023 Active, not recruiting --> Completed | Trial completion date: Sep 2022 --> Apr 2022 | Trial primary completion date: Sep 2022 --> Apr 2022
  • ||||||||||  ALX-001 / Allyx Therap
    Enrollment closed, Trial completion date, Trial primary completion date:  Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923 (clinicaltrials.gov) -  Jun 24, 2022   
    P1,  N=36, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Sep 2022 --> Apr 2022 | Trial primary completion date: Sep 2022 --> Apr 2022 Recruiting --> Active, not recruiting | Trial completion date: Jun 2022 --> Sep 2022 | Trial primary completion date: Jun 2022 --> Sep 2022
  • ||||||||||  ALX-001 / Allyx Therap
    Enrollment change, Trial completion date, Trial primary completion date:  Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923 (clinicaltrials.gov) -  Jan 28, 2022   
    P1,  N=36, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Jun 2022 --> Sep 2022 | Trial primary completion date: Jun 2022 --> Sep 2022 N=24 --> 36 | Trial completion date: Oct 2021 --> Jun 2022 | Trial primary completion date: Oct 2021 --> Jun 2022